Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Thomas Nutman · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $917,866 — Our work focuses on the host response to helminth infection and pathogenesis of helminthic disease; immune responses in pulmonary and extrapulmonary tuberculosis; modulation of immune responses in tuberculosis by coinfections and comorbidities such as helminth infections, undernutrition, obesity, vi…
Andrea Marzi · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $8,179,925 — Filovirus pathogenesis 1. Tai Forest virus (TAFV) causes severe disease and lethality in cynomolgus macaques TAFV is a lesser-known ebolavirus that has caused one reported human case of infection in Ivory Coast in 1994. The patient developed dengue-like symptoms including fever and rash and was evac…
KIM HASENKRUG · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $6,755 — We have completed initial studies to determine whether the depletion of the myeloid-biased hematopoietic stem cells that predominate in aged mice would result in repopulation with stem cells balanced in production of both lymphocytes and myeloid cells. Studies in depleted mice have shown rejuvenati…
Audray Harris · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $13,102 — Coronaviruses remain both a seasonal health burden and pandemic threat due to the antigenic variation of viral glycoproteins and the ability of animal coronaviruses to cause zoonotic infections in humans. Although conserved epitopes have been identified, there is a fundamental gap in understanding a…
Heinrich Feldmann · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $208,265 — The global public health burden caused by SARS-CoV-2 and its resulting disease, COVID-19, has driven the rapid development of vaccines and treatment options. However, the continued emergence of novel SARS-CoV-2 variants of concern (VOC), which rapidly and globally replace earlier, previously predomi…
Noah M Merin · CEDARS-SINAI MEDICAL CENTER · 2022 · $402,829 — ABSTRACT Project 2 Project 2 of this U54 application is co-lead by Michael Karin (communicating PI) and Moshe Arditi (co-PI). This project will investigate the effect of pre-infection co-morbidities on the clinical outcome of SARS-Cov-2 infection. The novel severe acute respiratory syndrome coron…
Pamela J Bjorkman · ROCKEFELLER UNIVERSITY · 2022 · $1,507,637 — Project 3: Summary/Abstract SARS-CoV-2, a newly-emergent betacoronavirus in the sarbecovirus genus, resulted in a global pandemic in 2020, infecting millions and causing COVID-19 disease. Two other zoonotic betacoronaviruses, SARS-CoV (a sarbecovirus) and MERS-CoV (a merbecovirus), also resulted in …
Neil King · UNIVERSITY OF WASHINGTON · 2022 · $958,363 — PROJECT SUMMARY – CORE A: PROTEIN SCIENCES Core A (Protein Sciences) will provide essential support to our Projects and Cores in three areas: protein production and characterization, high-resolution structure determination, and process development and technology transfer. Core A’s protein production…
David Veesler · UNIVERSITY OF WASHINGTON · 2022 · $881,853 — PROJECT SUMMARY – PROJECT 1: Definition of the structural principles underlying broadly protective humoral immunity Although the COVID-19 pandemic has accelerated the development of SARS-CoV-2 vaccines at an unprecedented pace, no licensed vaccines elicit broad protection against a large spectrum of…
Michael R. Farzan · SCRIPPS RESEARCH INSTITUTE, THE · 2022 · $1,876,244 — SUMMARY Coronaviruses, including SARS-CoV-2, pose obvious and imminent dangers to public health. This CAMPP proposal develops compounds that target multiple coronaviruses proteins and replication processes. These proteins include well established drug targets such as protease (Project 1) and replica…
Sanghyun Lee · BROWN UNIVERSITY · 2022 · $198,702 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19). Spike protein is the primary antigenic target for COVID vaccines and interfering with the interface between RBD (Receptor Binding Domain) of spike and ACE2 is the mechanism of …
MING LUO · UNIVERSITY OF MINNESOTA · 2022 · $8,177,132 — Project 1 – Small Molecule Entry Inhibitors of Pandemic Viruses ABSTRACT Coronaviruses (CoVs), arenaviruses (Arv), flaviviruses (FLAVs) and filoviruses (FiVs) are enveloped viruses. During virus entry, receptor binding and refolding of the fusion protein, followed by lipid mixing, are three essenti…
HANJOON RYU · 2022 · $4,158,139 — Qorvo Biotechnologies’ (Qorvo) investigational Bulk Acoustic Wave (BAW) sensor detection platform (Omnia TM ) targets viral antigen testing for use in Point-of-Care (POC) settings. The platform is designed to produce reliable and quantitative results matching central lab performance and improving …
Kerry L Burnstein · MIAMI VA HEALTH CARE SYSTEM · 2022 — COVID-19 poses a tremendous health threat, particularly to individuals overrepresented in the US Veteran community. COVID-19 mortality is greater in men than in women; while this disparity is at least partially due to factors such as higher rates of smoking, a hormonal link is likely and can be rapi…
Tyler Nelson Starr · FRED HUTCHINSON CANCER CENTER · 2022 · $128,574 — PROJECT SUMMARY SARS-related coronaviruses (also known as sarbecoviruses) circulate in bat reservoirs, but two human spillovers in the past 20 years—SARS-CoV-1 in 2002 and SARS-CoV-2 in 2019—have caused globally devastating outbreaks. The emergence of SARS-CoV-2 from a previously unknown bat lineage…
Wah Chiu · STANFORD UNIVERSITY · 2022 · $165,085 — Herpesviruses are pathogens of medical and economic significance that cause a range of diseases in humans and animals. Varicella-zoster virus (VZV) is an important human alpha herpesvirus that causes varicella and zoster after reactivation from latency in sensory ganglia. The morphogenesis of varice…
John R Cirrito · WASHINGTON UNIVERSITY · 2022 · $444,332 — ABSTRACT/PROJECT SUMMARY Coronavirus 2019 (COVID-19) has afflicted 6.2 million Americans and killed 190,000 as of early September 2020 (WHO website); a roughly 3% mortality. Between a shortage in testing and unidentified asymptomatic individuals, the actual number of those infected could be 6 to 24…
Matthew Reed Steinhart · INDIANA UNIVERSITY INDIANAPOLIS · 2022 · $51,752 — ABSTRACT Neurofibromatosis Type 2 (NF2) is a genetic condition in which specific types of tumors form in various locations throughout the body. Though the majority of these tumors grow slowly, the location of certain tumors can cause significant dysfunction. One of these tumor types grows on the ves…
Suzie H. Pun · UNIVERSITY OF WASHINGTON · 2022 · $455,938 — PROJECT SUMMARY The SARS-CoV-2 coronavirus, the cause of the COVID-19 global pandemic, is efficiently spread and has reached over 27 million confirmed cases as of September 8, 2020. There is therefore an urgent need for new technologies that can provide early detection of virus, reducing the transmi…
Mahesh B Chandrasekharan · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2022 · $190,625 — Project summary: ChIP-seq has enabled the mapping of genomic occupancy of many chromatin factors and epigenetic histone modifications, linked to normal growth and development and to the pathogenesis of many human diseases. ChIP-seq can also measure changes in the occupancy levels of epigenomic marks…